Linjie Zhao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4010409/publications.pdf

Version: 2024-02-01

33 papers	1,448 citations	471509 17 h-index	434195 31 g-index
35 all docs	35 docs citations	35 times ranked	2727 citing authors

#	Article	IF	Citations
1	Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer. Cancer Research, 2017, 77, 1369-1382.	0.9	184
2	Tumor microenvironment: The culprit for ovarian cancer metastasis?. Cancer Letters, 2016, 377, 174-182.	7.2	149
3	Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Research, 2020, 30, 833-853.	12.0	149
4	Glioma Stem Cellâ€“Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling. Cancer Discovery, 2019, 9, 1248-1267.	9.4	120
5	Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Science Translational Medicine, 2019, 11, .	12.4	112
6	Epigenetics in ovarian cancer: premise, properties, and perspectives. Molecular Cancer, 2018, 17, 109.	19.2	87
7	MicroRNAs in colorectal cancer: Small molecules with big functions. Cancer Letters, 2015, 360, 89-105.	7.2	80
8	The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts. Genome Biology, 2018, 19, 35.	8.8	68
9	Nuclear receptors: recent drug discovery for cancer therapies. Endocrine Reviews, 2019, 40, 1207-1249.	20.1	65
10	Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3673-E3681.	7.1	56
11	Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. Oncogene, 2019, 38, 2305-2319.	5.9	41
12	LncRNAs: the bridge linking RNA and colorectal cancer. Oncotarget, 2017, 8, 12517-12532.	1.8	33
13	The expression and functionality of stromal caveolin 1 in human adenomyosis. Human Reproduction, 2013, 28, 1324-1338.	0.9	28
14	Menopause-induced uterine epithelium atrophy results from arachidonic acid/prostaglandin E2 axis inhibition-mediated autophagic cell death. Scientific Reports, 2016, 6, 31408.	3.3	26
15	Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. Science Advances, 2021, 7, .	10.3	25
16	RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. Npj Precision Oncology, 2019, 3, 13.	5.4	23
17	Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence. Oncogene, 2022, 41, 895-906.	5.9	22
18	Wolfâ€“Hirschhorn Syndrome Candidate 1 (whsc1) Functions as a Tumor Suppressor by Governing Cell Differentiation. Neoplasia, 2017, 19, 606-616.	5.3	20

#	Article	IF	Citations
19	Nuclear Receptors in Cancer Inflammation and Immunity. Trends in Immunology, 2020, 41, 172-185.	6.8	19
20	A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. Molecular Cell, 2022, 82, 1123-1139.e8.	9.7	18
21	A mass spectrometric insight into the origins of benign gynecological disorders. Mass Spectrometry Reviews, 2017, 36, 450-470.	5.4	16
22	Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy. IScience, 2020, 23, 101458.	4.1	15
23	Increased expression of fibroblast growth factor receptor 1 in endometriosis and its correlation with endometriosis-related dysmenorrhea and recurrence. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 184, 117-124.	1.1	13
24	Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. Oncogene, 2021, 40, 6059-6070.	5.9	13
25	Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. Science Translational Medicine, 2022, 14, eabf3917.	12.4	13
26	Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges. Trends in Cancer, 2021, 7, 541-556.	7.4	11
27	eIF3i activity is critical for endothelial cells in tumor induced angiogenesis through regulating VEGFR and ERK translation. Oncotarget, 2017, 8, 19968-19979.	1.8	9
28	Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. Journal of Experimental Medicine, 2021, 218, .	8.5	9
29	A simple method based on Sanger sequencing and MS Word wildcard searching to identify Cas9-induced frameshift mutations. Laboratory Investigation, 2017, 97, 1500-1507.	3.7	5
30	Immunoregulatory Functions of Nuclear Receptors: Mechanisms and Therapeutic Implications. Trends in Endocrinology and Metabolism, 2020, 31, 93-106.	7.1	5
31	Functional Peptides and Small Molecules in Medicinal Chemistry-Part I. Current Topics in Medicinal Chemistry, 2019, 19, 2-3.	2.1	1
32	Functional Peptides and Small Molecules in Medicinal Chemistry-Part II. Current Topics in Medicinal Chemistry, 2019, 19, 186-186.	2.1	0
33	Complementing the tumor-specific immunity in tumor radiotherapy. Annals of Translational Medicine, 2016, 4, 289-289.	1.7	0